Dermatology Times Newsletter

To view this email as a web page, click here.

Skin Cancer Synopsis

Nasal reconstruction after skin cancer surgery

Dermatologists should consider the features of the nasal defect when weighing options for repair.

Learn more.

New challenges of melanoma

Melanoma rates continue to rise, especially thin lesions which represents the largest group of fatalities.

Learn more.

We want to hear from you!

Join our Reader Reactor Panel

We are inviting members of our community to join our Reader Reactor Panel. This select group of individuals will help our brand keep the pulse on important issues facing you and your colleagues today.

Would you like to join us?

In case you missed it

Diagnosing melanoma

New era looming in MCC treatment

World-wide skin cancer epidemiology

DIGITAL EDITION

March features

Wound healing technologies, updated rosacea guidelines, nasal reconstruction and more are all inside this month's issue of Dermatology Times.

Catch up on today's trends

JOB OPPORTUNITIES

AZ - Integrated Dermatology

CA - Integrated Dermatology

CO - Integrated Dermatology

CO - Leavitt Management Group

CT - Integrated Dermatology

CT - Advanced Dermatology

Washington,DC-Integrated Dermatology

FL - Eye Associates

FL - Integrated Dermatology

FL - Leavitt Management Group

GA - Leavitt Management Group

IL - Integrated Dermatology

LA - Integrated Dermatology

MA - Integrated Dermatology

MA - Reliant Medical Group

MD - Integrated Dermatology

MI - Leavitt Management Group

National - Integrated Dermatology

National - Leavitt Management Group

NC - Integrated Dermatology

NY - Integrated Dermatology

OH - Leavitt Management Group

OR - Cynthia Dreyer MD

PA - Leavitt Management Group

PA - Milton S Hershey Medical Center

TX - Snyder Dermatology

VA - Integrated Dermatology

WI - Gundersen Lutheran Health System

Have you ever asked, "How do treatment outcomes compare between botulinum toxins"? Dermatology Times and Cosmetic Surgery Times conducted a survey.

See the results. »

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT